| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943621 | ABBVIE | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(4 years from now) | |
| US7737142 | ABBVIE | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE49110 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
| USRE49302 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
| USRE47350 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
Vraylar is owned by Abbvie.
Vraylar contains Cariprazine Hydrochloride.
Vraylar has a total of 5 drug patents out of which 0 drug patents have expired.
Vraylar was authorised for market use on 17 September, 2015.
Vraylar is available in capsule;oral dosage forms.
Vraylar can be used as treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine, treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine, adjunctive therapy to antidepressants for the treatment of major depressive disorder.
Drug patent challenges can be filed against Vraylar from 18 September, 2019.
The generics of Vraylar are possible to be released after 17 September, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-904) | Dec 16, 2025 |
| M(M-213) | Nov 09, 2020 |
| New Indication(I-798) | May 24, 2022 |
| New Chemical Entity Exclusivity(NCE) | Sep 17, 2020 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
NCE-1 date: 18 September, 2019
Market Authorisation Date: 17 September, 2015
Treatment: Adjunctive therapy to antidepressants for the treatment of major depressive disorder; Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine; Treatme...
Dosage: CAPSULE;ORAL
VRAYLAR family patents
